| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Myrosin (100 μg/mL; 24 h) causes cells to be arrested in the G0/G1 phase of the cell cycle and raises p21 and p27 expression [1]. The accumulation of lipid droplets and the formation of fat were significantly inhibited by the expression of EBPα, PPARγ, leptin, and aP2. Early in adipocyte proliferation, Sinigrin can increase AMPK, MAPK, and coenzyme A phosphorylase (ACC) phosphorylation. This suggests that Sinigrin has an anti-adipogenic effect by activating AMPK, MAPK, and ACC [1]. Pro-inflammatory cytokines, such as TNF-α and IL-6, IL-1β, and IL-18, are inhibited by myrosin (1-100 μg/mL; 8 days).
|
|---|---|
| ln Vivo |
By boosting antioxidant enzymes and modifying the MAPK buffer inhibitory marker cascade, myrosin (15–30 mg/kg; vessel wall; for 12 days) has both preventive and therapeutic benefits in DSS sensor vasculitis [2].
|
| Cell Assay |
Cell cycle analysis [1]
Cell Types: 3T3-L1 adipocytes Tested Concentrations: 100 μg/mL Incubation Duration: 24 h Experimental Results: Cell cycle G0/G1 phase arrest, p21 and p27 expression increased. Western Blot Analysis[1] Cell Types: 3T3-L1 Adipocyte Tested Concentrations: 1, 10 and 100 μg/mL Incubation Duration: 8 days Experimental Results: Dramatically inhibited lipid droplet accumulation and adipogenesis by downregulating the expression of CCAAT enhancer binding protein alpha (C/EBPα), PPARγ, leptin, and aP2. RT-PCR[1] Cell Types: 3T3-L1 Adipocyte Tested Concentrations: 1, 10 and 100 μg/mL Incubation Duration: 8 days Experimental Results: Inhibition of pro-inflammatory cytokine production, including TNF-α and IL-6, IL- 1β and IL-18. |
| Animal Protocol |
Animal/Disease Models: Dextran sodium sulfate (DSS)-induced mouse model [2]
Doses: 15 mg/kg or 30 mg/kg Route of Administration: po (po (oral gavage)) lasted for 12 days Experimental Results: Dramatically diminished DSS-induced weight loss and diminished colon Length shrinkage, and improved disease index scores. successfully eliminated DSS-induced IL-17 levels and improved the colon barrier in colon tissue. |
| References |
|
| Molecular Formula |
C10H16KNO9S2
|
|---|---|
| Molecular Weight |
397.4636
|
| Exact Mass |
415
|
| CAS # |
3952-98-5
|
| Related CAS # |
534-69-0 (Parent);64550-88-5 (monohydrate salt/solvate)
|
| PubChem CID |
23684362
|
| Appearance |
White to off-white solid
|
| Melting Point |
128 (dec.)(lit.)ºC
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
23
|
| Complexity |
509
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
[K+].S(/C(/C([H])([H])C([H])=C([H])[H])=N\OS(=O)(=O)[O-])[C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O1)O[H])O[H])O[H]
|
| InChi Key |
QKFAFSGJTMHRRY-FVDOMRANSA-M
|
| InChi Code |
InChI=1S/C10H17NO9S2.K/c1-2-3-6(11-20-22(16,17)18)21-10-9(15)8(14)7(13)5(4-12)19-10;/h2,5,7-10,12-15H,1,3-4H2,(H,16,17,18);/q;+1/p-1/b11-6-;/t5-,7-,8+,9-,10+;/m1./s1
|
| Chemical Name |
potassium;[(Z)-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanylbut-3-enylideneamino] sulfate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~12.5 mg/mL (~31.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5160 mL | 12.5799 mL | 25.1598 mL | |
| 5 mM | 0.5032 mL | 2.5160 mL | 5.0320 mL | |
| 10 mM | 0.2516 mL | 1.2580 mL | 2.5160 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
